The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead ...

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...

Eli Lilly became the second drugmaker this week to sue the U.S. government for rejecting their proposed changes to a program ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Eli Lilly (LLY) files lawsuit against U.S. health agency over 340B Program rebates, alleging arbitrary blockage of its cash ...

Lee Munson, president and CIO at Portfolio Wealth Advisors, joins CNBC’s ‘Power Lunch’ to discuss outlooks on three stocks: ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), retaining the price target of $970.00. Don't Miss our Black Friday Offers: David Risinger ...

Evercore ISI analyst Umer Raffat maintained a Hold rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last ...

On Friday, Eli Lilly And Co (LLY) stock saw a decline, ending the day at $746.2 which represents a decrease of $-40.03 or -5.09% from the prior close of $786.23. The stock opened at $775.19 and ...